Skip to main content
. Author manuscript; available in PMC: 2017 Sep 20.
Published in final edited form as: Oncogene. 2017 Mar 20;36(29):4089–4099. doi: 10.1038/onc.2017.11

Fig. 4. Tumor-initiating cells exhibit increased iron dependence.

Fig. 4

(a) Cells were treated for 72 hrs with the indicated concentrations of deferoxamine (DFO) and viability was assessed using an MTS assay. (b) Cropped images of western blots of IRP2, transferrin receptor, (TFR1) ferritin heavy chain (FTH), and ferroportin in FTt cells with knockdown of IRP2 (IRP2 KD1, IRP2KD2) or control shRNA (shCtr). (c) Cell proliferation as assessed by trypan-blue exclusion in FTt cells treated with control shRNA or IRP2 knockdown vectors. d) Labile iron pool in cells with knockdown of IRP2 or control shRNA